| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Vesicular stomatitis virus glycoprotein (VSV-G). The peptide is derived from the VSV-G protein and is used as an epitope tag for protein detection and purification.
|
|---|---|
| ln Vitro |
VSV-G is a commonly used virus for pseudotyping artificial, lentiviral, and retroviral vectors. Ad293 cells can be infused with VSV-G, which can cause cell fusion and the transfer of cytoplasmic protein[1].
VSV-G peptide is used as a tag for protein expression and detection. It does not have intrinsic biological activity as a drug but is a valuable research tool. Ad293 cells infused with VSV-G can cause cell fusion and transfer of cytoplasmic protein. |
| ln Vivo |
No direct in vivo activity as a therapeutic agent; used as a tool for pseudotyping viral vectors in vivo. VSV-G pseudotyped lentiviral vectors are commonly used for in vivo gene delivery and tracking studies.
|
| Enzyme Assay |
VSV-G tag peptide is used in immunoprecipitation and Western blot assays. Antibodies against the VSV-G tag are employed to detect and pull down tagged proteins from cell lysates. Binding specificity is confirmed by competition assays with free peptide.
|
| Cell Assay |
VSV-G tagged proteins are expressed in mammalian cells (e.g., HEK293T, Ad293). Protein expression and localization are assessed by immunofluorescence or Western blot using anti-VSV-G antibodies. Cell fusion assays can be performed using Ad293 cells infused with VSV-G.
|
| Animal Protocol |
VSV-G pseudotyped lentiviral or retroviral vectors are administered to animal models for gene delivery studies. The VSV-G envelope protein enables broad tropism and efficient transduction of various cell types in vivo.
|
| ADME/Pharmacokinetics |
VSV-G tag Peptide (MW 1339.52) is a small peptide that is rapidly cleared from circulation. It is used as a research tool rather than a therapeutic agent, and detailed PK parameters are not relevant for this application.
|
| Toxicity/Toxicokinetics |
No toxicity data has been reported for VSV-G tag Peptide as it is a research tool, not a therapeutic agent. It is considered safe for standard laboratory use at recommended concentrations.
|
| References | |
| Additional Infomation |
VSV-G tag Peptide is an 11-amino acid peptide (YTDIEMNRLGK) derived from the vesicular stomatitis virus glycoprotein. It is widely used as an epitope tag for protein detection, purification, and localization studies. VSV-G pseudotyping is a standard method for producing high-titer lentiviral and retroviral vectors.
|
| Molecular Formula |
C57H94N16O19S
|
|---|---|
| Molecular Weight |
1339.52
|
| Exact Mass |
1338.66
|
| CAS # |
103425-05-4
|
| PubChem CID |
155977646
|
| Appearance |
White to off-white solid powder
|
| Density |
1.47±0.1 g/cm3(Predicted)
|
| LogP |
-8.6
|
| Hydrogen Bond Donor Count |
20
|
| Hydrogen Bond Acceptor Count |
23
|
| Rotatable Bond Count |
46
|
| Heavy Atom Count |
93
|
| Complexity |
2560
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
S(C)CC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(=O)O)CCCCN)=O)=O)CC(C)C)=O)CCC/N=C(\N)/N)=O)=O)NC([C@H](CCC(=O)O)NC([C@H]([C@@H](C)CC)NC([C@H](CC(=O)O)NC([C@H]([C@@H](C)O)NC([C@H](CC1C=CC(=CC=1)O)N)=O)=O)=O)=O)=O
|
| InChi Key |
JJVJQVAFUFUTGS-YGAXRUOQSA-N
|
| InChi Code |
InChI=1S/C57H94N16O19S/c1-7-29(4)45(72-53(88)40(26-44(80)81)71-55(90)46(30(5)74)73-47(82)33(59)24-31-13-15-32(75)16-14-31)54(89)68-35(17-18-43(78)79)50(85)67-36(19-22-93-6)51(86)70-39(25-41(60)76)52(87)66-34(12-10-21-63-57(61)62)49(84)69-38(23-28(2)3)48(83)64-27-42(77)65-37(56(91)92)11-8-9-20-58/h13-16,28-30,33-40,45-46,74-75H,7-12,17-27,58-59H2,1-6H3,(H2,60,76)(H,64,83)(H,65,77)(H,66,87)(H,67,85)(H,68,89)(H,69,84)(H,70,86)(H,71,90)(H,72,88)(H,73,82)(H,78,79)(H,80,81)(H,91,92)(H4,61,62,63)/t29-,30+,33-,34-,35-,36-,37-,38-,39-,40-,45-,46-/m0/s1
|
| Chemical Name |
(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 2 mg/mL (1.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7465 mL | 3.7327 mL | 7.4654 mL | |
| 5 mM | 0.1493 mL | 0.7465 mL | 1.4931 mL | |
| 10 mM | 0.0747 mL | 0.3733 mL | 0.7465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
